Intelligence · Clinical pipeline
Oncology · Phase II
Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.
Quick answer
Oncology Phase II programs: NovaPharmaNews indexes 2,637 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.
Top sponsors
- First People's Hospital 261 programs
- Chinese Academy of 198 programs
- George Institute for 118 programs
- United Therapeutics Europe 112 programs
- Telethon Foundation 91 programs
- Takeda 79 programs
- Regeneron UK 71 programs
- MSD Merck Sharp 63 programs
- Ningbo Cancer Hospital 62 programs
- Anaxis Pharma 57 programs
- AstraZeneca 52 programs
- HOFFMANN-LA ROCHE 50 programs
Pipeline programs
-
AK105 and anlotinib
The First People's Hospital of Lianyungang
Cervical Cancer
1 trial -
AK112
Summit Therapeutics
Metastatic Colorectal Cancer
1 trial -
AK112-210
Akeso
Metastatic Pancreatic Ductal Adenocarcinoma
1 trial -
AK117
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Head and Neck Squamous Cell Carcinoma
1 trial -
AL8326
Lacuna Pharma Pty Ltd
Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage., Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage.
1 trial -
AL8326
Lacuna Pharma Pty Ltd
- Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage. - Non Small Cell Lung Cancer (NSCLC) patients who need ≥2nd line treatment with brain metastasis which is controlled with no active hemorrhage. - Renal Cell Carcinoma (RCC) patients who need ≥2nd line treatment., - Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage. - Non Small Cell Lung Cancer (NSCLC) patients who need ≥2nd line treatment with brain metastasis which is controlled with no active hemorrhage. - Renal Cell Carcinoma (RCC) patients who need ≥2nd line treatment.
1 trial -
ALDESLEUKIN , TIL cells
Disc Medicine
Ovarian carcinoma
1 trial -
ALDESLEUKIN for Germ Cell Tumors refractory to salvage chemotherapy
The George Institute
Germ Cell Tumors refractory to salvage chemotherapy
1 trial -
ALECTINIB
Hoffmann-La Roche
ALK fusion-positive extracranial solid or primary CNS tumors who have progressed following prior treatment or who have no satisfactory treatment available
1 trial -
ALG.APV-527
Aptevo Therapeutics
Solid Tumor
1 trial -
ALKS4230-006
Wuhan Createrna Science and Technology Co., Ltd
Advanced cutaneous melanoma and Advanced mucosal melanoma
1 trial -
ALL2418
Fondazione Telethon ETS
Acute B-cell Lymphoblastic Leukemia with minimal residual positive disease prior to haematopoietic stem cell transplantation in adult patients
1 trial -
ALL2620
Fondazione Telethon ETS
Ph+ Acute Lymphoblastic Leukemia
1 trial -
ALL3024
Fondazione Telethon ETS
Very High-Risk T-Lineage Acute Lymphoblastic Leukemia (ALL)
1 trial -
ALLO-501A
Allogene Therapeutics
Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
1 trial -
ALLO-647
Allogene Therapeutics
Relapsed/Refractory Large B Cell Lymphoma
1 trial -
AMG 193
Amgen
Non-Small Cell Lung Cancer
1 trial -
AMG 706
Takeda
Advanced Gastrointestinal Stromal Tumor
1 trial -
AML1718
Fondazione Telethon ETS
Acute Myeloid Leukemia
1 trial -
AML2420
Fondazione Telethon ETS
Acute Myeloid Leukemia secondary to myeloproliferative neoplasms
1 trial -
AML2521
Fondazione Telethon ETS
Acute Myeloid Leukemia with NPM1 mutation
1 trial -
AP24534-14-203
Takeda
Chronic Phase Chronic Myeloid Leukemia
1 trial -
APG-2575CU101
Lacuna Pharma Pty Ltd
Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).
1 trial -
APHP190205
Pari Pharma GmbH
PRIMARY PLASMA CELL LEUKEMIA: A PROSPECTIVE PHASE II STUDY INCORPORATING DARATUMUMAB TO CHEMOTHERAPY AND STEM CELL TRANSPLANTATION
1 trial -
APHP200080
Pari Pharma GmbH
Newly diagnosed Glioblastoma (IDH wild-type) patients at initial radiological diagnosis eligible for tumor resection, and for the standard of care including concurrent temoradiation followed by adjuvant TMZ with or without Tumor Treating Fields*. (*Tumor Treating Fields is applicable only in participating centers in France)
1 trial -
APHP200132
Pari Pharma GmbH
children, adolescents and young adults with Acute Lymphoblastic Leukemia
1 trial -
APHP200133
Pari Pharma GmbH
Melanoma
1 trial -
APHP211176
Pari Pharma GmbH
Recently diagnosed non favorable Acute Myeloid Leukemias
1 trial -
APHP220729
Pari Pharma GmbH
Hepatocellular carcinoma
1 trial -
APHP220916
Pari Pharma GmbH
-women with an inflammatory HCA proven at histology and with at least one inflammatory HCA of more than 5 cm. -male with at least one inflammatory HCA proven at histology whatever the size and considered as non resectable by the multidisciplinary tumor board
1 trial -
APR-246
Aprea Therapeutics
Melanoma
1 trial -
APR-246
Aprea Therapeutics
Acute Myeloid Leukemia or Myelodysplastic Syndromes
1 trial -
APR-246
Aprea Therapeutics
Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53
1 trial -
APR-246
Aprea Therapeutics
High-grade Serous Ovarian Cancer
1 trial -
APR-246 (eprenetapopt) + Acalabrutinib in CLL
Aprea Therapeutics
Non Hodgkin Lymphoma
1 trial -
APR-246 (eprenetapopt) + Pembrolizumab
Aprea Therapeutics
Bladder Cancer
1 trial -
APX005M
Pyxis Oncology
Melanoma
1 trial -
ARC-21(EDGE-Gastric)
Arcus Biosciences
Upper Gastrointestinal Tract Cancer, Advanced Upper Gastrointestinal Tract Malignancies, Gastrointestinal Tract Malignancies
1 trial -
ARC-9
Arcus Biosciences
Metastatic colorectal cancer
1 trial -
ARD6122
Regeneron UK Limited
Neoplasms
1 trial -
ARI-HER2
The George Institute
Patients with HER2Positive Advanced Breast Cancer
1 trial -
ART27.13-100
ARTELO BIOSCIENCES, INC.
Cancer Anorexia
1 trial -
ART6043C001
Lacuna Pharma Pty Ltd
Metastatic solid tumors, Advanced solid tumors
1 trial -
ASCAPE-based follow-up strategy
ATOSSA THERAPEUTICS, INC.
Breast Cancer
1 trial -
ASLAN001
Hospital Authority, Hong Kong
Advanced/ Metastatic Hepatocellular Carcinoma
1 trial -
ASND0029
Lacuna Pharma Pty Ltd
Locally advanced or metastatic solid tumor malignancies, platinum resistant ovarian cancer, post-anti-pd-1 melanoma, second line or later cervical cancer, neoadjuvant melanoma and neoadjuvant non-small cell lung cancer, post-anti-pd-L1 non-small cell lung cancer, post-anti-pd-L1 small cell lung cancer, second line or later HER2+ breast cancer
1 trial -
ASND0038
Lacuna Pharma Pty Ltd
Stage III-IVA Resectable Locoregionall Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
1 trial -
ASP3082, DEXTROSE INJECTION / BRADEX 5%
The George Institute
Metastatic Non-small cell lung cancer (NSCLC) and Pancreatic ductal adenocarcinoma
1 trial
Frequently asked questions
How many oncology Phase II programs exist?
2,637 programs match both the therapeutic area and stage filters in our published index.